Skip to content

Study · Non-randomized trial · n = 41 · 2014

1 result

[The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people].

Kitachev KV, Sazonov AB, Kozlov KL, Petrov KIu, Sliusarev AS, Khavinson VKh

Advances in gerontology = Uspekhi gerontologii1 Jan 2014Cited by 2 (Europe PMC)

PMID25051774 (opens in a new tab)PepBankPUB-25051774
Publisher pageAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with vasculogenic erectile dysfunction, Vezugen monotherapy significantly improved penile arterial blood flow compared with pretreatment assessments.

    In plain wordsIn patients with vascular erectile dysfunction, Vezugen improved penile arterial blood flow compared with before treatment.

    Peptide
    Vesugen (KED)
    Outcome
    IncreasePenile arterial blood flow
    Study

    n = 41

    Comparator
    Before monotherapy
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The results show that the blood flow through the main artery of the penis after Vezugen treatment significantly improved both clinical and by objective indicators.
    3 context sentences
    Summary · context
    The objective of the study was to assess the effectiveness of vasoactive tripeptide Vezugen in patients with vasculogenic erectile dysfunction as manifestation of atherosclerosis.
    Summary · context
    Treatment results of erectile dysfunction in 41 patients were studied.
    Summary · context
    A comparative analysis of clinical and instrumental parameters of blood flow in the main penile arteries before and after monotherapy was undertaken.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 17:05 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.